File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Paclitaxel-eluting stents for chronically occluded saphenous veingrafts (EOS) study

TitlePaclitaxel-eluting stents for chronically occluded saphenous veingrafts (EOS) study
Authors
KeywordsAged
Angiocardiography
Article
Bypass Surgery
Chronic Disease
Clinical Article
Controlled Study
Coronary Stent
Drug Eluting Stent
Female
Follow Up
Heart Infarction
Human
Male
Percutaneous Coronary Intervention
Priority Journal
Restenosis
Revascularization
Saphenous Vein Graft
Survival Rate
Treatment Outcome
Vein Occlusion
Issue Date2010
PublisherBlackwell Publishing, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1540-8183
Citation
Journal Of Interventional Cardiology, 2010, v. 23 n. 1, p. 40-45 How to Cite?
AbstractObjectives: The aim of this study was to report the feasibility, short- and medium-term results of percutaneous coronary intervention (PCI) on saphenous vein graft (SVG) chronic total occlusions (CTO) using paclitaxel-eluting stents (PES). Background: In postbypass patients, PCI on SVG CTO, rather than native vessel CTO, is another treatment option. However, the acute procedural and medium-term outcomes are unknown. Methods: Twenty-two consecutive, symptomatic postbypass patients underwent PCI on SVG CTO; angiographic success was seen in 16 patients (73%). The successful cases were evaluated at 1 year; restudy angiography was performed at 11 ± 5 months in 15 patients (94%). Results: The patients had a mean age of 73 years with predominance of male (68%); the mean SVG age was 14 years. On average, patients received 3.4 PESs per lesion; the stent size was 3.5 ± 0.4 mm with a total stent length of 98 ± 34 mm. The use of embolic protection devices and glycoprotein IIb/ IIIa inhibitors was observed in 6 (38%) and 5 (31%) patients, respectively. The in-hospital major adverse cardiac event (MACE) was 13%, accountable by 2 patients with postprocedure myocardial infarction. At follow-up, 6 patients had angiographic restenosis (40%); there was 1 noncardiac death and 3 target vessel revascularizations. The 1-year MACE was 25%; the graft survival free of occlusion and revascularization was 56%. Conclusions: PCI on SVG CTO is a feasible approach with a fairly high success and low in-hospital complication. However, it is associated with a relatively high angiographic restenosis and MACE at 1 year. © 2010, Wiley Periodicals, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/134138
ISSN
2015 Impact Factor: 1.327
2015 SCImago Journal Rankings: 0.787
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorJim, MHen_HK
dc.contributor.authorHo, HHen_HK
dc.contributor.authorKo, RLYen_HK
dc.contributor.authorSiu, CWen_HK
dc.contributor.authorYiu, KHen_HK
dc.contributor.authorLau, CPen_HK
dc.contributor.authorChow, WHen_HK
dc.date.accessioned2011-06-13T07:20:04Z-
dc.date.available2011-06-13T07:20:04Z-
dc.date.issued2010en_HK
dc.identifier.citationJournal Of Interventional Cardiology, 2010, v. 23 n. 1, p. 40-45en_HK
dc.identifier.issn0896-4327en_HK
dc.identifier.urihttp://hdl.handle.net/10722/134138-
dc.description.abstractObjectives: The aim of this study was to report the feasibility, short- and medium-term results of percutaneous coronary intervention (PCI) on saphenous vein graft (SVG) chronic total occlusions (CTO) using paclitaxel-eluting stents (PES). Background: In postbypass patients, PCI on SVG CTO, rather than native vessel CTO, is another treatment option. However, the acute procedural and medium-term outcomes are unknown. Methods: Twenty-two consecutive, symptomatic postbypass patients underwent PCI on SVG CTO; angiographic success was seen in 16 patients (73%). The successful cases were evaluated at 1 year; restudy angiography was performed at 11 ± 5 months in 15 patients (94%). Results: The patients had a mean age of 73 years with predominance of male (68%); the mean SVG age was 14 years. On average, patients received 3.4 PESs per lesion; the stent size was 3.5 ± 0.4 mm with a total stent length of 98 ± 34 mm. The use of embolic protection devices and glycoprotein IIb/ IIIa inhibitors was observed in 6 (38%) and 5 (31%) patients, respectively. The in-hospital major adverse cardiac event (MACE) was 13%, accountable by 2 patients with postprocedure myocardial infarction. At follow-up, 6 patients had angiographic restenosis (40%); there was 1 noncardiac death and 3 target vessel revascularizations. The 1-year MACE was 25%; the graft survival free of occlusion and revascularization was 56%. Conclusions: PCI on SVG CTO is a feasible approach with a fairly high success and low in-hospital complication. However, it is associated with a relatively high angiographic restenosis and MACE at 1 year. © 2010, Wiley Periodicals, Inc.en_HK
dc.languageengen_US
dc.publisherBlackwell Publishing, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1540-8183en_US
dc.relation.ispartofJournal of Interventional Cardiologyen_HK
dc.subjectAgeden_US
dc.subjectAngiocardiographyen_US
dc.subjectArticleen_US
dc.subjectBypass Surgeryen_US
dc.subjectChronic Diseaseen_US
dc.subjectClinical Articleen_US
dc.subjectControlled Studyen_US
dc.subjectCoronary Stenten_US
dc.subjectDrug Eluting Stenten_US
dc.subjectFemaleen_US
dc.subjectFollow Upen_US
dc.subjectHeart Infarctionen_US
dc.subjectHumanen_US
dc.subjectMaleen_US
dc.subjectPercutaneous Coronary Interventionen_US
dc.subjectPriority Journalen_US
dc.subjectRestenosisen_US
dc.subjectRevascularizationen_US
dc.subjectSaphenous Vein Graften_US
dc.subjectSurvival Rateen_US
dc.subjectTreatment Outcomeen_US
dc.subjectVein Occlusionen_US
dc.subject.meshAgeden_HK
dc.subject.meshAngioplasty, Balloon, Coronaryen_HK
dc.subject.meshAntineoplastic Agents, Phytogenic - therapeutic useen_HK
dc.subject.meshChronic Diseaseen_HK
dc.subject.meshCoronary Angiographyen_HK
dc.subject.meshCoronary Artery Bypassen_HK
dc.subject.meshCoronary Restenosis - drug therapy - mortality - prevention & controlen_HK
dc.subject.meshDrug-Eluting Stentsen_HK
dc.subject.meshFeasibility Studiesen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGraft Occlusion, Vascular - drug therapy - surgery - therapyen_HK
dc.subject.meshHong Kongen_HK
dc.subject.meshHospital Mortalityen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshPaclitaxel - therapeutic useen_HK
dc.subject.meshRegistriesen_HK
dc.subject.meshSaphenous Vein - transplantationen_HK
dc.subject.meshTime Factorsen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titlePaclitaxel-eluting stents for chronically occluded saphenous veingrafts (EOS) studyen_HK
dc.typeArticleen_HK
dc.identifier.emailSiu, CW:cwdsiu@hkucc.hku.hken_HK
dc.identifier.emailYiu, KH:khkyiu@hku.hken_HK
dc.identifier.authoritySiu, CW=rp00534en_HK
dc.identifier.authorityYiu, KH=rp01490en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1540-8183.2009.00525.xen_HK
dc.identifier.pmid20465719-
dc.identifier.scopuseid_2-s2.0-76749168072en_HK
dc.identifier.hkuros168586-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-76749168072&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume23en_HK
dc.identifier.issue1en_HK
dc.identifier.spage40en_HK
dc.identifier.epage45en_HK
dc.identifier.eissn1540-8183-
dc.identifier.isiWOS:000274241700007-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridJim, MH=6603860344en_HK
dc.identifier.scopusauthoridHo, HH=7401465369en_HK
dc.identifier.scopusauthoridKo, RLY=15020468300en_HK
dc.identifier.scopusauthoridSiu, CW=7006550690en_HK
dc.identifier.scopusauthoridYiu, KH=35172267800en_HK
dc.identifier.scopusauthoridLau, CP=35275317200en_HK
dc.identifier.scopusauthoridChow, WH=7402281062en_HK
dc.identifier.citeulike6801847-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats